Investors are shifting their focus from high-flying tech stocks, particularly in artificial intelligence, to more stable sectors like healthcare and retail amid growing concerns over geopolitical tensions and U.S. economic growth. This change in sentiment has led to notable recoveries for previously struggling stocks, such as Moderna and Target, both of which have outperformed the S&P 500 since the start of the year.
Moderna’s stock has surged nearly 70% as the company pivots from its pandemic-era reliance on vaccines to a broader growth strategy that includes seasonal vaccines and oncology. With expectations of up to 10% revenue growth this year, investors are eyeing potential buying opportunities, particularly on dips. Meanwhile, Target’s stock has jumped over 20% as new CEO Michael Fiddelke implements a turnaround plan focused on improving customer experience and product offerings, supported by a $2 billion investment.
For market professionals, both Moderna and Target present intriguing investment opportunities. Moderna’s recovery hinges on its growth initiatives, while Target’s lower valuation relative to peers suggests potential upside as its turnaround strategy unfolds.
Source: fool.com